1204313-91-6

Basic information

• Product Name: (R)-tert-butyl (1-(naphthalen-1-yl)ethyl)(3-(3-(trifluoromethyl)phenyl)propyl)carbamate
• Synonyms: (R)-tert-butyl (1-(naphthalen-1-yl)ethyl)(3-(3-(trifluoromethyl)phenyl)propyl)carbamate
• CAS NO: 1204313-91-6
• Molecular Weight: 457.536
• Mol File: 1204313-91-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (R)-tert-butyl (1-(naphthalen-1-yl)ethyl)(3-(3-(trifluoromethyl)phenyl)propyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl (1-(naphthalen-1-yl)ethyl)(3-(3-(trifluoromethyl)phenyl)propyl)carbamate(1204313-91-6)
• EPA Substance Registry System: (R)-tert-butyl (1-(naphthalen-1-yl)ethyl)(3-(3-(trifluoromethyl)phenyl)propyl)carbamate(1204313-91-6)

Safety Data

• Hazardous Substances Data: 1204313-91-6(Hazardous Substances Data)

Upstream product

• 518335-32-5 tert-butyl (R)-1-(naphthalen-1-yl)ethylcarbamate 
• 21172-43-0 methylsulfonyl-3-(3-trifluoromethylphenyl)propyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1207533-91-2 (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl-2-ene]-1-naphthalenemethaneamine hydrochloride 
• 1207534-31-3 C₂₇H₂₈F₃NO₂ 
• 226256-56-0 cinacalcet 
• 78573-45-2 3-[3-(trifluoromethyl)phenyl]propan-1-ol 
• 585-50-2 3-(3-trifluoromethylphenyl)propanoic acid 
• 3886-70-2 (R)-1-(1-Naphthyl)ethylamine 
• 1355993-08-6 (R)-tert-butyl-3-(3-chlorophenyl)propyl(1-(naphthalen-1-yl)-ethyl)carbamate 
• 1355993-09-7 (R)-tert-butyl 1-(naphthalen-1-yl)ethyl(3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)carbamate 
• 1355993-10-0 (R)-3-(3-((tert-butoxycarbonyl)(1-(naphthalen-1-yl)ethyl)amino)propyl)phenylboronic acid 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 22991-03-3 3-(3-chlorophenyl)propanol 

Downstream Products

• 364782-34-3 cinacalcet hydrochloride 
• 1609282-66-7 C₂₇H₂₉F₃⁽¹⁸⁾FNO₂ 

Relevant articles and documents

Cinacalcet intermediate and synthesis method of cinacalcet hydrochloride

The invention relates to a cinacalcet intermediate and a synthesis method of cinacalcet hydrochloride. The synthesis method of cinacalcet hydrochloride comprises the steps of (c) in an organic solvent, carrying out olefin metathesis reaction on a compound N-III and a compound B-2 under the action of a catalyst to obtain a compound C-I; (d) carrying out hydrogenation reduction reaction on the compound C-I to obtain a compound C-II; and (e) removing an amino protecting group from the compound C-II, and salifying with hydrogen chloride to obtain cinacalcet hydrochloride. The method has the advantages of high yield, high chemical purity and optical purity of the product, simple post-treatment process, simple and easily available raw materials, and facilitation of industrial production. The reaction formula is shown in the description, wherein R is selected from t-butyloxycarbonyl, benzoyl and carbobenzoxy.

Copper-catalyzed oxidative trifluoromethylation of terminal alkynes and aryl boronic acids using (trifluoromethyl)trimethylsilane

Trifluoromethylated acetylenes and arenes are widely applicable in the synthesis of pharmaceuticals and agrochemicals. In 2010, our group has reported the copper-mediated oxidative trifluomethylation of terminal alkynes and aryl boronic acids. This method allows a wide range of functional group tolerant trifluoromethylated acetylenes and arenes to be easily prepared. After the preliminary mechanistic studies of the oxidative trifluoromethylation of terminal alkyne, an efficient copper-catalyzed oxidative trifluoromethylation of terminal alkynes and aryl boronic acids has been developed. The catalytic protocol is successfully achieved by adding both the substrate and a portion of CF3TMS slowly using a syringe pump to the reaction mixture.

HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl) phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1- naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3- (trifiuoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities.